Commit Biologics has announced the formation of a Scientific Advisory Board (SAB), bringing together leading experts in immunology, antibody engineering and molecular biology to guide the company’s development of complement-based therapeutics for autoimmune diseases and cancer.

The newly formed SAB will be co-chaired by Commit’s CEO Mikkel Wandahl Pedersen and internationally recognised antibody expert Janine Schuurman. Schuurman is known for her work advancing antibody therapeutics and brings substantial experience in translational research.

The company’s proprietary platform, known as Bispecific Complement Engager (BiCE), is designed to activate the complement system in a targeted way to destroy diseased cells while sparing healthy tissue. The SAB will play a strategic role in shaping the development of this platform, which the company believes has broad potential across multiple indications.

A board of seasoned scientific leaders

Alongside Schuurman and Pedersen, the board includes:

• Paul Parren, Professor of Molecular Immunology and a former SVP at Genmab. Parren has a long track record in antibody discovery and development, and co-founded several biotech companies.

• Gavin Thurston, former SVP of Oncology Research at Regeneron. Thurston brings deep oncology research expertise, particularly in translating basic science into drug development.

• Susan Kalled, an immunologist with leadership experience at Dianthus Therapeutics and Compass Therapeutics, where she served as Chief Scientific Officer. Her career spans academia and biotech, with a focus on autoimmune disease mechanisms.

• Esper Boel, a molecular biologist who previously served as CTO at Symphogen and as Corporate Vice President and Head of Biotechnology at Novo Nordisk. Boel has worked extensively on protein engineering and biologics development.

Guiding complement pathway innovation

The board’s primary function will be to provide strategic guidance to Commit’s leadership team and Board of Directors. According to the company, their collective insight will help shape the long-term direction of its BiCE platform and support translation of the science into clinically meaningful outcomes.

Mikkel Wandahl Pedersen, CEO of Commit Biologics, said: “Forming Commit’s Scientific Advisory Board is a pivotal step in our mission to bring first-in-class complement engager therapeutics to patients. I am very pleased that we have been able to gather such an accomplished group of people with deep immunology and drug-development experience. I am confident that their collective insight will sharpen our strategy and accelerate advancement of our pipeline.”

Commit, headquartered in Aarhus, Denmark, is developing a new class of targeted immunotherapies based on selective complement activation. The company says its BiCE technology enables dual targeting—binding both the complement system and disease-specific cell surface markers—to direct immune responses more precisely than existing approaches.